Join Us!

Duke University Health System has integrated Barostim into its comprehensive heart failure program. For patients with heart failure with reduced ejection fraction (HFrEF), Barostim is a device therapy that works with drug therapies to target the neurohormonal pathways responsible for heart failure progression and symptoms. Listen in as an advanced heart failure specialist discusses patient selection and post-implant management, the implant procedure, patient care pathways, and how Duke has incorporated Barostim into their system. And gain insight from a hospitalist and revenue cycle administrator who shares the lessons her team has learned on effectively submitting claims and managing denials, how payers handle prior authorizations and collaborating to optimize payment.

Here’s what we’ll cover in the session: 

• Why heart failures diagnoses will surge from 7 million to 9 million by 2030 
• Understanding the value of integrating Barostim into a comprehensive heart failure program 
• How drug therapies and Barostim target the neurohormonal pathways responsible for heart failure progression – and how to identify patients earlier 
• Timelines for starting a program and the key role the physician champion needs to play 
• Patient outcomes and new data on reducing hospitalizations 
• Gain insight on patient scheduling, coverage and coding for inpatient and outpatient procedures 
• How CVRx supports programs in getting started and ensuring appropriate reimbursement for all cases 
• How facilities can actively navigate prior authorization and remove barriers to payment in a ‘very manageable’ way

Expert Panel: 

Marat Fudim, MD, MHS Medical Director, Device Clinic and Director of Research at the Heart Center, Duke University Health System

Joanna Kipnes, MD, MS, FHM Associate Chief Medical Officer within the Patient Revenue Management Organization and Medical Director of Utilization Management, Duke University Health System

Bonnie Handke, RN, MBA Vice President of Patient Access, Reimbursement and Healthcare Economics, CVRx

Why This Matters 

With this real-time insight on building a solid program paired with knowledge on authorizations and beating denials, we’re equipping heart failure teams with new tools to treat patients effectively, build and grow strong programs and awareness with referrers, save administrative time and optimize payment for every patient.

Who should attend: 

• Cardiologists
• Advanced Heart Failure
• Cardiology and Heart Failure Administrators
• Reimbursement Professionals and Administrators
• Revenue and Utilization Management Administrators
• Heart Teams
• Cardiovascular Service Line Directors
• Advanced Practice Providers and Nurse Practitioners
• Hospital and Health System C-Suite: COOs, CEOs, CFOs
• Vascular and Cardiothoracic Surgeons